SKINMED® TRIPLELOCK® ROSACEA PROTOCOL
SkinMed® Rosacea TripleLock® is a preferred treatment choice of Professor Tony Chu
Professor and Senior Lecturer, Imperial College London and President of the Acne & Rosacea Association UK
How common is Rosacea?
Rosacea affects around 1 in 10 adults, which equates to around 5 million people suffering from rosacea in the UK alone, around 4 million of which fall into the target audience of most aesthetic clinical practices. Over 4 million women over 35 have vascular rosacea (including perimenopausal flushing) or papulopustular rosacea.
Men also suffer and have more sever symptoms but they often do not present. However these should be considered as a target also
New Rosagate® Range
Medically licenced for Vascular and Papulopustular Rosacea. Clinically proven to target both visible symptoms and root causes.
🔹 6 synergistic actives reduce inflammation, irritation, and papules
🔹 Inhibit neurogenic inflammation and histamine-driven responses
🔹Reduces visible blood vessels by moderating excess vascular growth
🔹 Boost skin tolerance to internal and external triggers
🔹 Protect integrity of blood vessels to maintain ability to contract
🔹Reduce the depth, frequency, and duration of flushing
Outstanding results
Clinical trials involved long term sufferers who had failed on multiple other GP, pharmacy, online treatments.
After just 1 week improvements were seen and at 4 weeks results were continuously improving in all triallists with continuous ongoing reduction in flushes, papules, pustules and thread vein improvement. These medical licensed formulas with novel new patented ingredients worked better than antibiotics, azelaic acid, metronidazole, pimecrolimus, ivermectin, low dose doxycycline, alpha and beta sympathetic agonists
EnerPeel® MA for Vascular Rosacea
EnerPeel® MA is a professional mandelic acid procedure medically licensed for vascular rosacea. Its patented carrier technology delivers 20% mandelate and 5% MSM to support vasoconstriction, regulate excessive VEGF activity and reduce the appearance of flushing and thread veins.
Used alongside Rosagate® Professional and the SkinMed® TripleLock® Rosacea Protocol, EnerPeel® MA helps clinics address vascular and inflammatory pathways through a structured, practitioner led treatment programme.
The Complete SkinMed® Rosacea Protocol
SkinMed® TripleLock® Rosacea Protocol combines SkinMed® EnerPeel® MA (mandelic acid) licensed for vascular rosacea with SkinMed® Rosagate® Professional in clinic treatment every one or two weeks with Rosagate® 24 Hr Cream, Rosagate® SPF50 day cream and Rosagate® Mask often used in the evening or over-night.
This forms an all-encompassing treatment that not only addresses the triggers and symptoms of Rosacea but improves the functionality of partially damaged and dilated blood vessels to function better and contract, due to the vasoconstrictive effect of SkinMed® EnerPeel® MA plus RO-peptide 23s activity on reducing and resisting papules and pustules.
The Science and the Solution
SkinMed® Synchorose® Formula is medically licensed for the treatment of Rosacea, and clinically proven to address all visible symptoms and underlying triggers using a unique combination of 4 key active ingredients. These work synergistically to build up the skin’s tolerance to internal and external triggers, short-circuiting reddening reactions as they occur while also working to reduce inflammation and irritation. SkinMed® have added fast erythema reducing ingredients and flushing receptor triggering inhibitors, with Rosacea Trigger Tolerance Threshold raising ingredients using key lipid boosters to reduce the incidence, depth and length of flushing episodes. SkinMed® retinoids are added to our SkinMed® Protocols to sustain results for the long term.
How common is Rosacea?
Rosacea affects around 1 in 10 adults, which equates to around 5 million people suffering from rosacea in the UK alone, around 4 million of which fall into the target audience of most aesthetic clinical practices.
The Complete SkinMed® Rosacea Protocol
The complete SkinMed® TripleLock® Rosacea Protocol combines SkinMed® Synchrorose® with SkinMed® Tebiskin®, SkinMed® SkinVital® and SkinMed® EnerPeel® MA, forming an all-encompassing treatment that not only addresses the triggers and symptoms of Rosacea but improves the functionality of partially damaged and dilated blood vessels to function better and contract, due to the vasoconstrictive effect of SkinMed® EnerPeel® MA.
Outstanding results
Clinical trials involved rosacea sufferers who were part of the Rosacea Support Group, all of whom were long-standing sufferers who had tried almost everything else available on the market. After just 8 weeks, an astonishing 75% of these patients with difficult to treat symptoms found the products successful in managing their rosacea, proving SkinMed® Synchrorose® to be more effective than antibiotics
Please click on the booklet below to read more on our Amazing Protocols.
Use The Instruction Bar Below to Scroll pages, Zoom in, Or Full Page.
SkinMed ® Clinical Enerpeel Treatments recommended for successfully delivering this protocol include
The Expert Know About Us
Just read what they have to say
Become SkinMed Accredited…
Enhance your knowledge, expertise, customer numbers and satisfaction – we do what others don’t-
Join the 1,250 (and counting) medical professionals that have taken their clinical practice to the next level by completing their SkinMed® Accreditation
